Join our daily newsletter At The Bell to receive exclusive market insights
- Paradigm Biopharmaceuticals (PAR) appoints experienced pharmaceutical industry executive Marco Polizzi as its new CEO, effective July 1
- With over 30 years of experience in the field, Mr Polizzi has a proven track record highlighted by several successful business and product launches in the US, according to PAR
- During his career, he established the Mallinckrodt’s Brand Pharmaceutical business unit from scratch, which is now a multi-billion-dollar revenue division of Mallinckrodt
- Mr Polizzi says he believes he will be able to make a “significant contribution” to the Paradigm business in the short and long term
- Paradigm last traded at $1.21 per share on May 27
Paradigm Biopharmaceuticals (PAR) has appointed experienced pharmaceutical industry executive Marco Polizzi as its new CEO, effective July 1.
With over 30 years of experience in the field, Mr Polizzi has a proven track record highlighted by several successful business and product launches in the US, according to Paradigm.
During his career, he established the Mallinckrodt’s Brand Pharmaceutical business unit from scratch. The business is now a multi-billion-dollar revenue division of Mallinckrodt.
Paradigm Chairman Paul Rennie said Mr Polizzi’s broad expertise would lead Paradigm in attaining its strategic program objectives and increase shareholder value.
“Paradigm has been seeking a CEO with the skills to fully unlock the commercial value of the company,” Mr Rennie said.
“Marco brings to Paradigm extensive US pharmaceutical experience, a pharmaceutical industry network, operational excellence, transactional expertise, product launch and product pricing, and reimbursement experience.”
Meanwhile, Mr Polizzi said he believed he would be able to make a “significant contribution” to the Paradigm business in the short and long term given his pharmaceutical experience.
“I have had the opportunity to meet the Paradigm board and key management
personnel, and I can say Paradigm’s business excites me,” he said.
“[This is] primarily on account of Zilosul — a blockbuster potential product that may bring relief to the millions of people globally suffering from the pain and other debilitating effects of osteoarthritis and significantly increase shareholder returns.”
Paradigm last traded at $1.21 per share on May 27.
